Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dopamine β-hydroxylase (DBH) is an enzyme that catalyzes the conversion of dopamine to norepinephrine, a critical step in catecholamine biosynthesis. It is essential for maintaining proper levels of dopamine and norepinephrine, influencing blood pressure, body temperature, mood, and other autonomic functions. Mutations or variants in the DBH gene can lead to Dopamine β-hydroxylase deficiency, characterized by impaired norepinephrine production and severe autonomic dysfunction. Decreased serum DBH activity has been observed in various neurological diseases, suggesting potential diagnostic utility.
Inhibition of dopamine conversion to norepinephrine (potential)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dopamine β-hydroxylase (None).